Results and Impact of the Follow-Up of the NeoALTTO Trial
Carlos L. Arteaga, MD, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
Clinical Pearls
Carlos L. Arteaga, MD, professor of medicine and cancer biology, Vanderbilt-Ingram Cancer Center, discusses the results and impact of the four-year follow-up analysis of the NeoALTTO trial, which analyzed patients with HER2-positive breast cancer.
- The NeoALTTO trial set out to determine whether the higher pathologic complete response (pCR) rate achieved with lapatinib plus trastuzumab translated into better overall survival or event-free survival
- The hazard for event-free survival was 65%-70% lower for patients who achieved pCR than for those who did not
- This trial is important because the FDA now allows for the approval of novel therapies following testing in the adjuvant setting
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
